ArticleVeterinary dermatology2026
A Retrospective Case Series Reporting the Clinical Efficacy and Adverse Events of Oclacitinib Administration for Skin Disease in 238 Cats.
Article in Veterinary dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Retrospective Case Series Reporting the Clinical Efficacy and Adverse Events of Oclacitinib Administration for Skin Disease in 238 Cats.Veterinary dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOff-label oclacitinib use for feline dermatoses management is increasing despite the paucity of data regarding optimal dose and adverse events (AEs).
objectiveReview AEs, clinical efficacy, and dose regimens in cats prescribed oclacitinib. MATERIALS AND
methodsRetrospective case series of 238 privately owned cats prescribed oclacitinib for dermatological disease. Signalment, history, laboratory abnormalities, oclacitinib dosage (mg/kg/day), treatment duration and AEs using a modified Naranjo Adverse Drug Reaction Probability Scale were retrieved from medical records spanning August 2014 to May 2024. Clinical efficacy was estimated using a pruritus Visual Analogue Scale and medical record lesional descriptions; categorised as complete, partial or no response.
resultsThe mean (x̄) initial dosage prescribed was 1.89 mg/kg/day. Monotherapy controlled clinical signs in 140 of 238 cats (59%), including 83 of 140 cats (59%) on twice daily (x̄ = 1.85 mg/kg/day) and 57 of 140 cats (41%) on once daily administration (x̄ = 1.05 mg/kg/day). The median treatment duration was 271.5 days (range 1 day-7.5 years). Main diagnoses successfully managed included feline atopic skin syndrome (61%) and pemphigus foliaceus (29%). Thirty-three 'definite' or 'probable' AEs were observed in 32 of 238 cats including: neutropaenia 6.3% (n = 15), gastrointestinal 4% (n = 9), lethargy 1.7% (n = 4), infection 0.8% (n = 2), hyperactivity 0.4% (n = 1), elevated alanine transaminase 0.4% (n = 1) and elevated creatinine 0.4% (n = 1). CONCLUSIONS AND CLINICAL RELEVANCE: Off-label oclacitinib administration in cats appeared to be well-tolerated and effective with AEs typically mild, responsive to dose reduction, and similar to those reported in dogs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.